Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Valueworks LLC

Valueworks LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,903 shares of the biopharmaceutical company's stock after selling 7,970 shares during the quarter. Valueworks LLC's holdings in Gilead Sciences were worth $1,931,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the 4th quarter worth approximately $28,000. Crews Bank & Trust purchased a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Stephens Consulting LLC boosted its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new position in Gilead Sciences in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Up 3.6%

Shares of NASDAQ GILD opened at $106.16 on Tuesday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm has a market capitalization of $132.06 billion, a PE ratio of 286.92, a PEG ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The business has a 50-day moving average price of $105.60 and a two-hundred day moving average price of $99.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the business earned ($1.32) EPS. The business's quarterly revenue was down .3% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Royal Bank of Canada increased their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Friday, April 25th. Finally, BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at $17,893,713.60. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 22,929 shares of company stock valued at $2,634,220. Corporate insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.